Clinical Trial Update: A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating avelumab in combination with axitinib for non-small cell lung cancer or urothelial cancer has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Urothelial Cancer

Drugs mentioned

• Avelumab (avelumab)
• Axitinib (Axitinib)

Snippet

Sponsor: Pfizer | Conditions: Non-Small Cell Lung Cancer, Urothelial Cancer | Phase 2 | Status: TERMINATED | Results posted: 2024-04-09